🇸🇬Singapore IP Company, UK-Resident Owner: The IDI Box Meets UK CFC Rules

Concept

The idea is attractive: move the intellectual property into a Singapore company, apply for the IP incentive, pay 5–10% instead of UK rates, while the family stays in the UK. Both halves of that sentence are regulated: Singapore's incentive is conditioned on real R&D nexus, and the UK reads a UK-managed foreign company — or a UK-controlled one — as its own tax base. The structure survives only when the Singapore side is genuinely Singaporean.

The Singapore Side: What the IDI Actually Is

The IP Development Incentive is Singapore's patent-box regime, administered by the EDB under s.43X of the Income Tax Act 1947 (introduced in Budget 2017, effective 1 July 2018; EDB circular verified 2026-08-19 at edb.gov.sg). Core parameters:

• Rate: 5% or 10% on a percentage of qualifying IP income (the percentage follows the modified nexus approach — benefits track R&D expenditure contributing to the IP); for companies approved on or after 17 February 2024 the base rate can also be 15%, with at least +0.5% step-ups in the later five-year periods (ITA s.43X(5)-(6) — verified 2026-08-19 at sso.agc.gov.sg). No new IDI approvals after 31 December 2028 (s.43X(2)).
• Scope: royalties and other income from elected qualifying IP rights — patents and copyright in software; the election into the regime is irrevocable.
• Term: an initial incentive period of up to ten years, extendable in periods of up to ten years each, with progress reporting to EDB and revocation for breach.
• Conditions: expansionary projects and substantive economic activities in Singapore; arm's-length related-party dealing with contemporaneous transfer-pricing documentation submittable to IRAS.

The UK Side: Two Ways the UK Reaches the Company

Residence first: under UK case law a company is UK-resident if its central management and control is exercised in the UK — board-level decisions by UK-resident family members can move the company's residence wholesale, before any CFC analysis begins (verify current HMRC practice at gov.uk).

CFC second: Part 9A of TIOPA 2010 charges UK corporate controllers holding a 25%+ relevant interest in a UK-controlled foreign company on an apportioned share of its chargeable profits at UK corporation tax rates, with credit for foreign tax — IP-derived income is squarely within the gateway categories the regime targets (legislation.gov.uk, TIOPA 2010 Part 9A — verified 2026-08-19). For individual family shareholders, the transfer-of-assets-abroad code (ITA 2007, s.721 ff.) is the parallel personal-level risk: income of the foreign company can be treated as the individual's where value was transferred abroad and the transferor can enjoy it. Both regimes have exemptions and motive defences — but they are pleaded with evidence, not asserted.

The Substance Question Both Sides Ask

The IDI's nexus condition and the UK's management test point at the same facts: who does the R&D, where, and who decides. If the family's UK members perform the DEMPE functions — development, enhancement, maintenance, protection, exploitation — from the UK, the Singapore percentage shrinks toward zero on the nexus formula and the UK argument grows. The working version: R&D teams and IP decisions in Singapore, UK family members as passive shareholders with documented non-involvement in management, and a written motive narrative for why the IP sits in Asia (market, team, history) — see economic substance and Singapore holding × EU founders for the management-layer mechanics.

Sources

• Singapore EDB — IP Development Incentive circular (verified 2026-08-19)
• legislation.gov.uk — Taxation (International and Other Provisions) Act 2010, Part 9A (verified 2026-08-19)
• HMRC — controlled foreign companies guidance (verify current practice)